Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Purchased by Voya Investment Management LLC

Voya Investment Management LLC lifted its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 371,235 shares of the biopharmaceutical company's stock after purchasing an additional 97,602 shares during the period. Voya Investment Management LLC owned about 0.24% of Ocular Therapeutix worth $3,170,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Artisan Partners Limited Partnership boosted its position in Ocular Therapeutix by 26.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company's stock valued at $11,398,000 after buying an additional 278,610 shares during the last quarter. Rosalind Advisors Inc. boosted its holdings in Ocular Therapeutix by 27.5% in the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company's stock valued at $9,639,000 after purchasing an additional 243,700 shares during the last quarter. First Trust Advisors LP acquired a new stake in Ocular Therapeutix during the 4th quarter valued at approximately $1,819,000. Raymond James Financial Inc. purchased a new stake in Ocular Therapeutix during the 4th quarter worth approximately $1,722,000. Finally, RoundAngle Advisors LLC purchased a new stake in Ocular Therapeutix during the 4th quarter worth approximately $1,695,000. 59.21% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares of the company's stock, valued at approximately $24,184,584.66. The trade was a 0.61 % decrease in their position. The disclosure for this sale can be found here. 3.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

OCUL has been the subject of a number of recent analyst reports. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They set an "outperform" rating and a $17.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. JMP Securities set a $19.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Needham & Company LLC reissued a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, April 8th. Finally, William Blair began coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $16.38.

Ocular Therapeutix Stock Performance

NASDAQ:OCUL traded down $1.07 during midday trading on Monday, reaching $7.73. 3,676,801 shares of the company traded hands, compared to its average volume of 1,445,646. Ocular Therapeutix, Inc. has a twelve month low of $4.79 and a twelve month high of $11.78. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The company has a fifty day moving average price of $7.40 and a 200 day moving average price of $8.39. The firm has a market capitalization of $1.23 billion, a price-to-earnings ratio of -5.86 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million for the quarter, compared to analyst estimates of $16.89 million. On average, analysts expect that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.